The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion
Abstract
AS03 is an Adjuvant System composed of α-tocopherol, squalene and polysorbate 80 in an oil-in-water emulsion. In various nonclinical and clinical studies, high levels of antigen-specific antibodies were obtained after administration of an AS03-adjuvanted vaccine, permitting antigen-sparing strategies. AS03 has been shown to enhance the vaccine antigen-specific adaptive response by activating the innate immune system locally and by increasing antigen uptake and presentation in draining lymph nodes, a process that is modulated by the presence of α-tocopherol in AS03. In nonclinical models of the AS03-adjuvanted prepandemic H5N1 influenza vaccine, increased levels of anti-influenza antibody afforded protection against disease and against virus replication of influenza strains homologous and heterologous to the vaccine strain. By incorporating AS03 in the pandemic H1N1/2009 vaccine, vaccine immunogenicity was increased compared with nonadjuvanted H1N1 vaccines. High H1N1/2009/AS03 vaccine effectiveness was demonstrated in several assessments in multiple populations. Altogether, the nonclinical and clinical data illustrate the ability of AS03 to induce superior adaptive responses against the vaccine antigen, principally in terms of antibody levels and immune memory. In general, these results support the concept of Adjuvant Systems as a plausible approach to develop new effective vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Updating the accounts: global mortality of the 1918–1920 "Spanish" influenza pandemic.
Johnson, N. P. A. S., & Mueller, J. (2002) · Bulletin of the History of Medicine · doi:10.1353/bhm.2002.0022 · Cited by 1,980
Vitamin E: function and metabolism
Brigelius‐Flohé, R., & Traber, M. G. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.10.1145 · Cited by 1,591
Vitamin E, antioxidant and nothing more
Traber, M. G., & Atkinson, J. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.03.024 · Cited by 1,478
Hayden, M. S., West, A. P., & Ghosh, S. (2006) · Oncogene · doi:10.1038/sj.onc.1209943 · Cited by 1,178
The rgp120 HIV Vaccine Study Group (2005) · The Journal of Infectious Diseases · doi:10.1086/428404 · Cited by 952
Stoute, J. A., Slaoui, M., Heppner, D. G., Momin, P., Kester, K. E., Desmons, P., Wellde, B. T., Garçon, N., Krzych, U., Marchand, M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701093360202 · Cited by 870
Self-citationMiller, E., Hoschler, K., Hardelid, P., Stanford, E., Andrews, N., & Zambon, M. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62126-7 · Cited by 708
Safety and Immunogenicity of an Inactivated Subvirion Influenza A (H5N1) Vaccine
Treanor, J. J., Campbell, J. D., Zangwill, K. M., Rowe, T., & Wolff, M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055778 · Cited by 698
Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in china
Han, F., Lin, L., Warby, S. C., Faraco, J., Li, J., Dong, S. X., An, P., Zhao, L., Wang, L. H., Li, Q. Y., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22587 · Cited by 512
Leroux-Roels, I., Borkowski, A., Vanwolleghem, T., Dramé, M., Clement, F., Hons, E., Devaster, J.-M., & Leroux-Roels, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61297-5 · Cited by 498
Cited by
Emerging concepts in the science of vaccine adjuvants
Pulendran, B., S. Arunachalam, P., & O’Hagan, D. T. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00163-y · Cited by 1,385
SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
Kyriakidis, N. C., López-Cortés, A., González, E. V., Grimaldos, A. B., & Prado, E. O. (2021) · npj Vaccines · doi:10.1038/s41541-021-00292-w · Cited by 698
Correlates of adjuvanticity: A review on adjuvants in licensed vaccines
Del Giudice, G., Rappuoli, R., & Didierlaurent, A. M. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.05.001 · Cited by 610
Self-citationThe how’s and what’s of vaccine reactogenicity
Hervé, C., Laupèze, B., Del Giudice, G., Didierlaurent, A. M., & Tavares Da Silva, F. (2019) · npj Vaccines · doi:10.1038/s41541-019-0132-6 · Cited by 513
Self-citationVaccine adjuvants: Understanding the structure and mechanism of adjuvanticity
Shi, S., Zhu, H., Xia, X., Liang, Z., Ma, X., & Sun, B. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.04.055 · Cited by 423
Vaccination in the elderly: The challenge of immune changes with aging
Ciabattini, A., Nardini, C., Santoro, F., Garagnani, P., Franceschi, C., & Medaglini, D. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.10.010 · Cited by 411
Recent Advances of Vaccine Adjuvants for Infectious Diseases
Lee, S., & Nguyen, M. T. (2015) · Immune Network · doi:10.4110/in.2015.15.2.51 · Cited by 385
COVID-19 Vaccine Frontrunners and Their Nanotechnology Design
Chung, Y. H., Beiss, V., Fiering, S. N., & Steinmetz, N. F. (2020) · ACS Nano · doi:10.1021/acsnano.0c07197 · Cited by 346
An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives
Facciolà, A., Visalli, G., Laganà, A., & Di Pietro, A. (2022) · Vaccines · doi:10.3390/vaccines10050819 · Cited by 316
Adjuvants: Classification,Modus Operandi, and Licensing
Apostólico, J. D. S., Lunardelli, V. A. S., Coirada, F. C., Boscardin, S. B., & Rosa, D. S. (2016) · Journal of Immunology Research · doi:10.1155/2016/1459394 · Cited by 287
Progress and Prospects on Vaccine Development against SARS-CoV-2
Zhang, J., Zeng, H., Gu, J., Li, H., Zheng, L., & Zou, Q. (2020) · Vaccines · doi:10.3390/vaccines8020153 · Cited by 282
The single-cell epigenomic and transcriptional landscape of immunity to influenza vaccination
Wimmers, F., Donato, M., Kuo, A., Ashuach, T., Gupta, S., Li, C., Dvorak, M., Foecke, M. H., Chang, S. E., Hagan, T., et al. (2021) · Cell · doi:10.1016/j.cell.2021.05.039 · Cited by 276
Tregoning, J. S., Russell, R. F., & Kinnear, E. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1415684 · Cited by 263
An Overview of Novel Adjuvants Designed for Improving Vaccine Efficacy
Bonam, S. R., Partidos, C. D., Halmuthur, S. K. M., & Muller, S. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.06.002 · Cited by 261
Recent progress in adjuvant discovery for peptide-based subunit vaccines
Azmi, F., Ahmad Fuaad, A. A. H., Skwarczynski, M., & Toth, I. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.27332 · Cited by 239
“It was reported that AS03 exhibit their adjuvanticity by enhancing antigen migration to lymph node and activating the innate immune system.(50) The immunostimulatory activity of AS03 is associated with the presence of α-tocopherol in their composition.”
BackgroundInnovative Vaccine Strategy: Self-Adjuvanting Conjugate Vaccines
Manabe, Y., & Fukase, K. (2023) · Methods in Molecular Biology · doi:10.1007/978-1-0716-2910-9_5 · Cited by 5
Metadata
- Authors
- Garçon, N., Vaughn, D. W., & Didierlaurent, A. M.
- Venue
- Expert Review of Vaccines
- Publisher
- Informa UK Limited
- Published
- 2012-01
- Volume
- 11
- Issue
- 3
- Pages
- 349-366
- ISSN
- 1476-0584 (ISSN-L)
- 1744-8395
- OpenAlex
- W2103783169
- Cited by
- 347
- References
- 80
- FWCI
- 12.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.